Emergent BioSolutions FY Conference Summary Company Overview - **Company Name**: Emergent BioSolutions (NYSE:EBS) - **Industry**: Biodefense and Opioid Overdose Treatment - **Established**: 25 years ago - **Mission**: Protect and save lives through biodefense products and opioid overdose treatments [3][4] Core Business Areas 1. **Biodefense Products**: - Portfolio includes 11 products targeting serious threats like smallpox, anthrax, botulism, and Ebola [4][11] - Collaborates with U.S. and global governments for vaccine and therapeutic development [4][12] 2. **Opioid Overdose Treatment**: - Market leader with Narcan for opioid overdose treatment [4][20] - Focus on increasing access to Narcan, aiming for widespread availability [21][22] Turnaround Plan - **Timeline**: Multi-year plan initiated in 2024 - **Phases**: 1. **Stabilization** (2024-2025): Streamlined operations, divested $150 million in assets, reduced operating expenses by $250 million, and improved Adjusted EBITDA from negative in 2023 to $183 million in 2024 [7][30] 2. **Turnaround** (2025-2026): Focus on growth investments, both organic and inorganic [9][10] 3. **Transformation** (2026 and beyond): Aim for a sustainable and profitable company [10][32] Financial Performance - **Debt Reduction**: Total debt reduced by $275 million since 2023, with net leverage down from 9.9 times to approximately 2 times [8][30] - **Revenue Trends**: Revenue decreased due to divestitures but Adjusted EBITDA margin improved from 19% in 2024 to 33% in 2025 [29][30] - **Future Guidance**: Projected Adjusted EBITDA for 2025 between $195-$210 million [7] Market Dynamics - **Geographic Diversification**: Revenue from outside the U.S. increased from 15% to 34% [19] - **Bipartisan Support**: Strong political backing for biodefense initiatives and opioid overdose solutions [15][16] Product Innovations - **Narcan Backpack Kit**: Recently approved by the FDA to enhance accessibility for potential users [22][23] - **Partnerships**: Collaborations with RocketVax for rapid vaccine development and Hikma for Kloxxado, a higher dose naloxone product [24][25] Pipeline and Future Opportunities - **Key Products**: Ebanga for Ebola, TEMBEXA for smallpox, and Raxibacumab for anthrax [26][28] - **Clinical Trials**: New trials for TEMBEXA in mpox treatment initiated [28] - **Growth Investments**: Focus on expanding international reach and developing new products [31][46] Challenges and Competitive Landscape - **Naloxone Market**: Anticipated mid-single-digit growth in overall naloxone unit volume, with Narcan expected to maintain market leadership [36][37] - **Funding Opportunities**: Potential $50 billion from opioid litigation settlements to support naloxone distribution [41] Conclusion - Emergent BioSolutions is on track with its turnaround plan, focusing on growth and innovation while maintaining a commitment to patient safety and quality [32][33]